The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study

Clinical Neuropharmacology

Volumn 23, Issue 2, 2000, Pages 82-85

  Snow, Barry J ^a   Macdonald, Lorraine ^a   Mcauley, David ^a   Wallis, William ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Amantadine; Dyskinesia; Parkinson's disease

Indexed keywords

AMANTADINE; LEVODOPA;

ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; AMANTADINE; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0033999316     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200003000-00004     Document Type: Article

References (13)

1. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study [see comments]. Ann Neurol 1996;40:355-66.
2. Albin RL, Young AB, Penney JB. The functional anatomy of disorders of the basal ganglia. TINS 1995;18:63-4.
3. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate agonist in parkinsonian monkeys. Ann Neurol 1996:39: 574-8.
4. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994;43:91-104.
5. Lang AE, Blair RDG. Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. New York: Springer-Verlag; 1989:307-23.
6. Rajput AH, Uitti RJ, Lang AE, Kumar R, Galvez-Jimenez N. Amantadine ameliorates levodopa induced dyskinesia [abstract]. Neurology 1997;48:A328.
7. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50:1323-6.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992;3:181-4.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, et al. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan, 1987:153-64.
11. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-4.
12. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-6.
13. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for Levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-6.